Applying the Risk of Bias Tool in a Systematic Review of Combination Long-Acting Beta-Agonists and Inhaled Corticosteroids for Persistent Asthma
2011

Assessing the Risk of Bias in Asthma Trials

Sample size: 107 publication Evidence: moderate

Author Information

Author(s): Hartling Lisa, Bond Kenneth, Vandermeer Ben, Seida Jennifer, Dryden Donna M., Rowe Brian H.

Primary Institution: University of Alberta

Hypothesis

How reliable is the Risk of Bias tool in evaluating asthma trials?

Conclusion

The Risk of Bias tool shows improved inter-rater reliability and highlights concerns about pharmaceutical industry influence in asthma research.

Supporting Evidence

  • 85% of trials had unclear allocation concealment.
  • 87% of trials were at high risk of bias.
  • 95% of trials were funded by the pharmaceutical industry.
  • Inter-rater agreement on RoB assessments was better than previously reported.
  • Median time to complete RoB assessments was 21 minutes.

Takeaway

This study looked at how well a tool works to check if asthma studies are fair and found that many studies might be biased because they were funded by drug companies.

Methodology

A systematic review of 107 RCTs was conducted, assessing risk of bias using the RoB tool, Jadad scale, and allocation concealment.

Potential Biases

High risk of bias was found in 87% of studies, primarily due to pharmaceutical industry funding.

Limitations

The study's homogeneity and small sample size may limit the ability to detect differences in effect estimates.

Digital Object Identifier (DOI)

10.1371/journal.pone.0017242

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication